Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/20/2006 First Published: 2/21/2003


1.		Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 80				Other				FRE-FNCLCC-GETUG-12/0203 EU-20238, NCT00055731

Last Modified: 9/19/2008 First Published: 7/26/2003


2.		Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-2402 BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13

Last Modified: 9/17/2008 First Published: 7/26/2003


3.		Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-25-02 BIG-3-02, NABCI-IBCSG-25-02, EU-20347, IBCSG-25-02, NCT00066703, EUDRACT-2004-000168-28

Last Modified: 5/14/2008 First Published: 2/18/2005


4.		Phase III Randomized Study of Neoadjuvant Androgen Blockade Therapy Comprising Triptorelin and Flutamide Followed by Conformal External Beam Radiotherapy and Continued Androgen Blockade Therapy Versus Conformal External Beam Radiotherapy Alone in Patients With Stage II or III Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				Other				FRE-FNCLCC-GETUG-14/0207 EU-20503, NCT00104741

Last Modified: 9/17/2008 First Published: 1/25/2006


5.		Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0521 RTOG-0521, NCT00288080

Last Modified: 9/18/2008 First Published: 5/11/2006


6.		Phase III Randomized Study of Zoledronate in Preventing Osteoporosis and Associated Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiotherapy and Luteinizing Hormone-Releasing Hormone Agonist Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				NCI				RTOG-0518 0518, RTOG-0518, NCT00329797


7.		HOBOE: A Study of Hormonal Adjuvant Treatment Effect on Bone Mineral Density in Early Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				Other				HOBOE NCT00412022

First Published: 4/23/2008


8.		Phase III Randomized Study of Immediate Versus Delayed Adjuvant Triptorelin and Radiotherapy in Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or IV Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				FNCLCC-GETUG-17/0702 FNCLCC-GETUG 17/0702, EU-20791, EUDRACT-2007-002495-34, NCT00667069

Last Modified: 11/6/2007 First Published: 9/12/2007


9.		Phase II Study of Neoadjuvant Therapy Comprising Complete Hormonal Blockade and Capecitabine, Methotrexate, and Vinorelbine Followed by Surgery and Adjuvant Therapy Comprising Paclitaxel or Capecitabine, Methotrexate, and Vinorelbine in Women With Hormone Receptor-Positive Resectable Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				FHCRC-6277 6277, UWCC-UW-6277, UWCC-03-8482-B-01, NCT00194792


10.		Investigation of Early Hormonotherapy Efficacy of Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Active				40 to 80				Other				KMU-Urol1 NCT00375687

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute